- Home
- LRE vs UNCY Comparison
LRE vs UNCY Comparison
Compare LRE & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- UNCY
- Stock Information
- Founded
- LRE 2001
- UNCY 2016
- Country
- LRE Japan
- UNCY United States
- Employees
- LRE N/A
- UNCY N/A
- Industry
- LRE
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- UNCY Health Care
- Exchange
- LRE Nasdaq
- UNCY Nasdaq
- Market Cap
- LRE 24.4M
- UNCY 91.0M
- IPO Year
- LRE 2023
- UNCY 2021
- Fundamental
- Price
- LRE $1.76
- UNCY $4.88
- Analyst Decision
- LRE
- UNCY Strong Buy
- Analyst Count
- LRE 0
- UNCY 4
- Target Price
- LRE N/A
- UNCY $63.75
- AVG Volume (30 Days)
- LRE 10.9K
- UNCY 1.2M
- Earning Date
- LRE 01-01-0001
- UNCY 08-13-2025
- Dividend Yield
- LRE N/A
- UNCY N/A
- EPS Growth
- LRE N/A
- UNCY N/A
- EPS
- LRE N/A
- UNCY N/A
- Revenue
- LRE $110,330,328.00
- UNCY N/A
- Revenue This Year
- LRE N/A
- UNCY N/A
- Revenue Next Year
- LRE N/A
- UNCY $1,458.53
- P/E Ratio
- LRE N/A
- UNCY N/A
- Revenue Growth
- LRE 3.92
- UNCY N/A
- 52 Week Low
- LRE $1.10
- UNCY $2.02
- 52 Week High
- LRE $2.49
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- LRE 54.52
- UNCY 43.02
- Support Level
- LRE $1.71
- UNCY $4.31
- Resistance Level
- LRE $1.78
- UNCY $5.55
- Average True Range (ATR)
- LRE 0.08
- UNCY 0.76
- MACD
- LRE -0.01
- UNCY -0.10
- Stochastic Oscillator
- LRE 28.78
- UNCY 16.26
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.